



The baked side: Cow's milk and egg protein threshold dose distributions in children reacting to baked milk and baked egg

Rocco Luigi Valluzzi, MD^{a*}, Carla Riccardi, MD^b, Sara Urbani, MD^b, Davide Ursi, MD^c, Deborah Zavettieri, MD^d, Francesco Di Girolamo, PhD^e, Lamia Dahdah, MD^b, Veronica Calandrelli, PharmD^b, Vincenzo Fierro, MD^b and Alessandro Fiocchi, MD^b

ABSTRACT

Background: Children allergic to milk and egg, but tolerant to baked products, display higher reactivity thresholds than the general population of children allergic to milk and egg. We sought to verify the reactivity thresholds of milk- and egg-allergic children who also react to baked milk and baked egg, respectively.

Methods: We retrospectively assessed consecutive oral food challenge (OFC) for baked milk and egg between January 2018 and March 2022 in a population of baked milk- and baked-egg allergic children.

Results: Among 407 children included (median age 56 - IQR 31.1–103.7 months, 67.1% male), 93 (23.6%) returned positive OFC results, 41 with baked milk, and 52 with baked egg. The most conservative ED01 was 0.4 mg total protein (IQR 0.1–2.7) for milk and 2.2 mg total protein (IQR 0.6–7.3) for egg. The respective ED05 was 3.9 (IQR 1.1–14) mg for milk and 11.7 (IQR 5–27.2) mg for egg. Such thresholds are consistent to those found for fresh milk (0.8 times for ED01, 1.1 times for ED05). For egg, they are 6.5 (egg ED01), and 7.5 (egg ED05) times lower than for native form. Compared to the currently used thresholds, they are 1.3 (milk ED01), 1.3 (milk ED05), 11 (egg ED01), and 4.9 (egg ED05) times higher.

Conclusions: Milk thresholds are similar to those already observed in baked allergic versus baked tolerant children, while EDs for egg are at least 1.6 times higher than those currently indicated. Egg-allergic patients could be exempt from the recommendations of absolute avoidance of foods when present in infinitesimal quantities, represented by precautionary allergen labelling based on current EDs.

Keywords: Challenge tests, Egg hypersensitivity, Food hypersensitivity, Milk hypersensitivity, Pediatrics

^aAllergy Unit, Piazza S. Onofrio Bambino Gesù Children's Hospital, IRCCS, 00165, Rome, Holy See, Italy

*Corresponding author. E-mail: roccoluigi.valluzzi@opbg.net

Full list of author information is available at the end of the article

<http://doi.org/10.1016/j.waojou.2024.101012>

Received 4 June 2024; Received in revised form 9 October 2024; Accepted 1 December 2024

Online publication date xxx

1939-4551/© 2024 Published by Elsevier Inc. on behalf of World Allergy Organization. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

INTRODUCTION

The clinical interest of the eliciting doses (EDs) in food allergy is growing.¹ In these patients, the probability of reacting to a specific food depends on the EDs. OIT (oral Immunotherapy) studies indicate that increasing the ED reduces the risk of an allergic reaction from accidental exposure,² and the use of anti-IgE reduces the likelihood and the severity of the reactions by increasing the threshold doses for different foods.³ It is, therefore, not surprising that the most recent and authoritative assessments confirm relying on the EDs to establish the precautionary labeling (PAL) limit, ie, the quantity of accidentally contaminating food below which it is not necessary to issue an alarm.⁴

The Voluntary Incidental Trace Allergen Labeling (VITAL) established doses to which one percent of the allergy patient population reacts (ED01) of 0.3 mg total protein for milk and 0.2 mg for egg.^{5,6} An ED05 of 3.1 mg for milk and 2.4 mg for egg has been calculated.⁵⁻⁸ Under this amount, the manufacturing companies are suggested to renounce to affix PAL alluding to the risk of allergic reactions. Such thresholds have been elaborated on published diagnostic challenges. For milk and egg in particular, none of the included studies distinguished patients tolerant or reactive to baked foods.⁹⁻³² Yet, due to structural changes of food proteins upon heating,³³ 69%–73% of children allergic to milk and egg seen at tertiary centers are tolerant to the baked forms,³⁴⁻⁴¹ and in an open population 80.3% of children with challenge-proven egg allergy tolerated a baked egg challenge.⁴² While retrospective studies suggests that children who tolerate baked egg are less sensitive to native egg compared with children with unknown baked reactivity,⁴³ the only published study comparing thresholds found similar ED10 and ED50 values in baked tolerant and baked-allergic children.⁴⁴ Based on it, it was argued that extensive heating of hen's egg and cow's milk in a food matrix impacts only marginally the threshold dose-distribution curves.

Recently, we found that the subpopulation of children allergic to milk/egg, but tolerant to baked proteins, displays higher reactivity thresholds than the population of children who are allergic to milk/

egg regardless of thermal processing.⁴⁵ This raises the question of whether children reactive to baked foods have lower thresholds. If so, they should be considered as a subpopulation of particular risk for clinical advice regarding the possible presence of allergenic contaminants in tiny quantities in commercial foods. To clarify this, we present here the EDs of children allergic to milk and egg who also react to baked proteins.

Caseload and methods study design

Bambino Gesù Children's Hospital is to a third-level hospital with a catchment area corresponding to the entire Italian nation. Our center accommodates various risk levels associated with food allergies. In it, patients with a history of immediate reactions to milk and/or egg sensitized to such foods are subjected to diagnostic oral food challenges (OFCs) on a scheduled basis in a programmed way, until they get tolerance.⁴⁶ OFCs are performed in an office setting with facilities for preparation, administration, and monitoring. Patients' reactions are assessed until objective symptoms appear. Those already consuming baked milk and/or egg get OFCs directly with raw milk and/or egg. Otherwise, patients are preliminarily evaluated for tolerance to baked milk and/or baked egg.⁴⁷ OFCs are not performed only in those patients with a recent anaphylactic reaction.⁴⁸

In this study, we retrospectively evaluated the thresholds of reactivity of consecutive children who underwent OFC for baked milk and/or baked egg between January 2019 and March 2022. For those who have repeatedly undergone OFC for the same food, we have included the first procedure for each type of food. Patients with a personal history of allergic reaction to both baked milk and baked egg performed 2 different OFCs.

Clinical suspicion was based on medical history, with admission symptoms grouped in patient medical records based on parental reports. We only considered children with a personal history of immediate mild to severe systemic reactions, developed up to 2 h after food consumption. Parents granted their written agreement after being fully aware of the risks of the procedure prior to the OFC. Sensitivity to the relevant foods was assessed on the day we delivered OFC using a skin prick test (SPT) and the determination of specific

IgE (slgE). Patients were excluded if both their slgE determination (cut-off 0.35 kU/L; ImmunoCAP Thermo Fisher, Uppsala, Sweden) and skin prick test (wheal Ø cut-off 3 mm; Lofarma, Milan, Italy) were below the cut-offs.

We performed a seven-step OFC, open or blinded double-blind, placebo-controlled food challenges (DBPCFC). We administered milk-free, egg-containing biscuits ("Novellino", Camporelli S.p.A., Novara, Italy; 2.09 g egg protein per 100 g product) for confirmation of baked egg allergy, and egg-free, milk-containing biscuits ("Biscottino Primi Mesi", Plasmon, Milano, Italy; 1.30 g milk protein per 100 g product) for confirmation of baked milk allergy.

Specifically, for baked milk, we set the lowest dose to 1.3 mg of protein and the total amount of protein to 837.2 mg, corresponding to 100 mg and 64.4 g of biscuits, respectively; for egg, we set the lowest dose to 2.1 mg and the total amount of protein at 1115 mg of proteins (about a 53.4 g of biscuits). Equivalent amount of baked milk and baked egg used in OFCs are reported in [Supplemental Table 1](#) in the Supplemental Materials. We derived the protein content of biscuits according to the product data sheets. Patients remained under observation for at least 2 h after the last dose.

All parents or legal tutors of the patients received information about the risks of OFCs, and written informed consent was obtained for each patient.

The institutional review board approved the protocol. We got approval from our local Ethic Committees to the use of such clinical data.⁴⁰

Symptom grading and threshold data

As suggested by the main guidelines, we performed OFCs in hospital with close supervision and immediate availability of emergency treatment. Our center accommodates various risk levels associated with food allergies. Low-risk OFCs are performed in an office setting with facilities for preparation, administration, and monitoring. The same clinicians observed and assessed the outcome of the oral food challenges, and doses were administered until objective symptoms appeared. For higher-risk challenges, we ensure necessary materials and support for treating severe reactions, including immediate

access to emergency services. The expected severity of symptoms and the need for equipment influences decisions regarding the location of an OFC. Where there is a significantly high risk of a severe reaction, it is preferable to conduct these challenges within the intensive care unit.^{49,50} We classified patient's reactive symptoms into 5 groups, from subjective symptoms (nausea, abdominal pain, pruritus, oral allergy syndrome) to systemic reactions.⁵¹ We designated the starting point at which objective symptoms appear at a dose as the Lowest Observed Adverse Effect Level (LOAEL) and the highest dose that does not produce any objective symptoms as the No Observed Adverse Effect Level (NOAEL).

According to previous studies, we choose an Interval-Censoring Survival Analysis (ICSA) approach to our data.^{45,52} To summarize, if a patient developed an objective reaction after the first dose, the NOAEL was considered being 0 and the LOAEL equal to the first dose (left censored). If a patient developed no objective reaction after the seventh dose, the entire cumulative dose was considered as NOAEL and the LOAEL set to infinity (right censored). If the patient discontinued the test because of subjective symptoms, we considered the final administered dose as right censored. In all other cases, interval-censoring occurs bounded by the NOAEL and LOAEL.

Statistical analysis

We used multivariate logistic regression analysis to assess independent predictors (age, sex, history of clinical manifestations, slgE level results or SPTs wheal size) of patients' individual LOAEL. A p-value less than 0.05 was considered statistically significant; slgE values > 100 kU/L received a designated value of 101 kU/L (JMP®, Version 15. SAS Institute Inc., Cary, NC, 1989-2023).

We used SAS 15.1 (SAS Institute, Cary, NC, U.S.A.) and LIFEREG procedure to fit parametric models to the interval-censored data. We considered Log-normal, log-logistic, and Weibull models to fit these data and to extrapolate EDs (ED01, ED05, ED10, ED25 and ED50), which are the doses predicted to elicit allergic reactions in 1%, 5%, 10%, 25%, and 50% of milk and egg-allergic patient, respectively.⁵³ Confidence intervals (CI) were calculated and added.

RESULTS

Patient characteristics

Of 442 consecutive patients evaluated in the period considered, excluding repeat testing, 229 completed baked milk, and 197 baked egg OFC. Nineteen patients, who referred a personal history of allergic reactions to both baked milk and baked egg, underwent both OFCs.

The mean age of the 407 patients was 74.8 months (SD 55.5). The median age is listed in Table 1, along with their clinical characteristics. Allergy tests results of 426 patients are reported in Table 2.

Of all OFCs assessed, 416 (97.7%) were open and 10 (2.3%) DBPCFC. None of the patients who underwent DBPCFC reacted to the placebo, and they were considered homogeneous with those who underwent open OFC.

One hundred sixty-nine patients reported possible allergic reactions both to milk and egg.

Forty-one (17.9%) of the 229 patients who completed OFC with baked milk had a positive result. Eleven of them had reported with a history of a severe systemic reaction,⁵¹ 15 reported allergic reactions to other foods (12 to egg), 15 had a history of atopic dermatitis, and 20 had a history of

respiratory disease, such as asthma and/or rhinitis, whether allergic or not fully diagnosed.

After challenge with baked milk, the most common symptoms were respiratory (28 patients, 68.3%). Nine patients (21.9%) developed only respiratory reactions: of them 3 were classified in Group 2, 4 in Group 3 (1 with throat pruritus or tightness), and 2 in Group 4. Three patients developed only skin reactions (2 with generalized urticaria) and 5 only gastrointestinal symptoms (4 with emesis). Twenty-four patients developed a systemic reaction (58.5%): 8 were included in Group 2, 4 in Group 3, and twelve in Group 4. Of the last patients, 4 developed localized urticaria and dyspnea, 3 generalized urticaria and dyspnea, 1 dyspnea, nausea, emesis and tachycardia, 1 generalized urticaria, dyspnea and tachycardia, 1 dyspnea and mild lip swelling, 1 dyspnea, nausea and emesis, and the last 1 localized urticaria, dyspnea, repetitive vomiting, mild hypotension and change in activity (this was the only patient of both groups that needed hospitalization).

Of the 197 patients who completed OFC with baked egg, 52 (26.4%) were positive. Forty-one patients reported allergic reactions to other foods (33 to milk), 21 a history of atopic dermatitis, and 29 a personal history of respiratory diseases;

	Baked Milk	Baked Egg	Total
Age (months), median (25th,75th percentile)	56 (30, 112)	56 (35, 99)	56 (31.2, 103.7)
Male, n (%)	156 (68.1)	130 (66)	286 (67.1)
Atopic dermatitis, n (%)	67 (29.2)	88 (44.7)	155 (36.4)
Respiratory disease, n (%)	73 (31.9)	91 (46.2)	164 (38.5)
Anaphylaxis, n (%)	44 (19.2)	39 (19.8)	83 (19.5)
ER visits in the clinical history, n (%)	18 (4.2)	18 (4.2)	36 (8.5)
User epinephrine in last year, n (%)	23 (5.4)	19 (4.5)	42 (9.8)
Challenges performed, n	229	197	426
OFC, n (%)	225 (98.3)	191 (97)	416 (97.6)
DBPCFC, n (%)	4 (1.7)	6 (3)	10 (2.3)
Positive outcome, n (% of performed challenges)	41 (17.9)	52 (26.4)	93 (20.4)
First dose responders, n (% of performed challenges)	1 (0.1)	-	1 (0.3)
LOAEL, mg	1.3	8.4	-

Table 1. Characteristics of 426 patients who completed OFC protocol. DBPCFC, double-blinded placebo-controlled food challenge; ER, Emergency room; LOAEL, lower observed adverse effect level; OFC, open food challenge.

	Positive skin prick test results, n (%) [Median; 25th-75th percentile]	Positive specific IgE assay results, n (%) [Median; 25th-75th percentile]
Baked milk (n=229)		
Milk (PTP)	127 (55.4) [9;6-13]	138 (60.3) [6.79; 1.84-39.12]
α -lactalbumin	91 (39.7) [6; 5-9.5]	93 (40.6) [2.55; 1.17-11.12]
β -lactoglobulin	105 (45.8) [6;4-9]	89 (38.9) [2.34; 0.70-8.71]
Casein	55 (24) [4;3-6]	90 (39.3) [8.46; 0.78-25.23]
Baked egg (n=197)		
Egg white	121 (61.4) [6;5-10]	127 (64.5) [3.23; 1.29-14.41]
Egg yolk	95 (48.2) [4;3-6]	90 (45.7) [2.13; 0.85-5.74]
Egg white (PTP)	96 (49.7) [8;5-11]	-
Egg yolk (PTP)	57 (28.9) [5;4-7]	-
Ovalbumin	-	78 (39.6) [2.29; 1.21-10.24]
Ovomucoid	-	61 (31) [2.97; 0.66-11]

Table 2. Allergy test results of the patients. PTP, prick to prick test.

only 12 reported an anaphylactic reaction in their medical history.

After baked egg food challenge, the most frequent symptoms were skin reactions (31 patients, 59.6%). Fifteen patients (28.8%) developed only skin reactions (11 classified in Group 1 and 4 with urticaria and/or angioedema in Group 2). Sixteen patients developed only gastrointestinal reactions, 10 with emesis (Group 2), 3 with repetitive vomiting (Group 3), and 3 with oral pruritus and mild lip swelling (Group 1). Only 2 patients developed a respiratory reaction, 1 with rhinorrhea and nasal congestion (Group 3) and 1 with dyspnea and wheezing (Group 4). Nineteen patients developed a systemic reaction during baked egg challenge (36.5%); 8 developed skin symptoms (mainly localized pruritus and urticaria) followed by emesis or repetitive vomiting: 5 were included in Group 2 and 3 in Group 3. Of the remaining patients with systemic reactions, 8 were classified in Group 2, 1 in Group 3, and 2 (with urticaria and dyspnea) in Group 4.

Of 19 patients with a personal history of allergic reaction to both baked foods, 15 tolerated both

baked foods. Two patients reacted only to baked milk (1 with nasal congestion and sneezing and 1 with rhinorrhea and marked congestion) and 1 patient only to baked egg (urticaria). One patient reacted to both baked foods, developing dyspnea during the baked milk OFC and urticaria during the baked egg OFC.

Only 1 patient challenged with baked milk developed objective symptoms at the first dose (left-censored) with a LOAEL of 1.3 mg milk. We observed 10 (24.3%) and 7 (13.4%) reactions after consuming the last dose of baked milk and baked egg, respectively (Fig. 1).

After logistic regression analysis, we found a significant correlation between the individual threshold dose and milk sIgE value only ($p < 0.001$). As reported in Fig. 3, higher levels of milk sIgE had a high probability of reacting at lower LOAEL, as well as the opposite ($OR = 0.82$; $CI_{95\%} = 0.96-0.99$). No significant correlation was found for other variables, such as age, sex, atopic diseases, referred manifestation, SPT wheal size, or type of symptoms developed at OFC.




Fig. 1 Symptom Score Group observed during baked milk and egg positive food challenges. The number of patients given to a particular dose is indicated in the plots. The intensity of gray shading denotes the percentage of challenged patients responding with a given symptom score.⁵¹

Eliciting doses

We fitted the data with log-normal, log-logistic, and Weibull distribution models (Fig. 2a and b) and extrapolated EDs from these models. The milk EDs ranged from 0.4 to 1.3 mg proteins (ED01), from 3.9 to 4.8 mg (ED05), from 8.9 to 10.4 (ED10), from 27.1 to 40.4 (ED25), and from 93.9 to 132.1 (ED50). The egg EDs ranged from 2.2 to 4.4 mg (ED01), from 11.7 to 15.9 (ED05), from 24.3 to 28.3 mg (ED10), from 54.9 to 69.5 (ED25) and from 135.7 to 172.5 mg (ED50) (Table 3).

DISCUSSION

Although the practice of performing OFCs with baked products is widespread,⁵⁴ few data are available specifically on the reactivity thresholds in baked milk/egg allergic children.⁴⁴ In this study, we confirm that children allergic to baked milk display threshold dose levels close to those observed for fresh milk. We found a prevalence

of positive challenges to baked milk of 17.9%, inferior to the 26.1% found for fresh milk, but consistent with the one discovered in previous investigations.^{36-38,47-61} This result is in line with previous research,^{44,55} although the similarity with the fresh milk EDs is more significant for the ED01 and ED05 (Table 3).

For baked egg, we found a prevalence of positive challenges of 26.4%, similar to some studies cited above.^{34,35} The thresholds we found for baked egg were consistently higher than for baked milk: our most conservative ED01 was 2.2 mg total protein (IQR 0.6–7.3), with an ED05 of 11.7 (IQR 5–27.2) mg. Such thresholds are 6.5 (egg ED01), and 7.5 (egg ED05) times lower than for native form. This contrasts with currently available data, which designates baked egg thresholds at levels similar to those of native egg.^{6,44} Recently, an ED01 of 1.4 mg for egg was identified in a population of children allergic to egg, but no data were collected for baked




Fig. 2 Comparison between the distribution curves of thresholds for baked cow's milk (A) and baked hen's egg (B) proteins, and the previously calculated distribution curves for these allergens in their pasteurized form (C-D), based on Log-normal, Log-logistic, and Weibull distribution models. The dashed lines indicate the 95% confidence interval

OFCs, due to the lack of standardized criteria for processing.⁶² However, a retrospective study suggested that children tolerant of baked egg react at higher EDs of native egg compared with those avoiding it.⁴³

Our prevalence of positive baked egg OFCs is lower than Turner et al (36%), who administered a




Fig. 3 Correlation between Individual threshold doses and milk sIgE levels. The axes measure sIgE levels and LOAEL percentages. Color-coded data points indicating different LOAEL values. Blue lines represent the correlation model and its 95% confidence intervals

total amount of 1 g protein.⁶³ In that study, 38 of the 86 reactive patients (44.2%) developed objective symptoms after the third of 4 doses. We found a similar result for raw egg (48.9% after the fifth of 7 doses), while of 52 patients positive to baked egg oral food challenge, 35 reacted after the 5th dose (67.3%). Indeed, only 1 of our 98 reactive patients (1%, including raw and baked egg OFCs) developed objective symptoms after the first dose of OFC with raw egg (LOAEL 12.36 mg).⁴⁵ These findings indicate that reactivity is not directly dependent on the amount of protein administered, and that there is no concordance between the meal (pasteurized or baked egg) administered in oral food challenge and the most conservative ED01 theorized in VITAL protocol (0.03 mg, raw egg white). Of note, the only patient who reacted after the first dose of baked milk developed a more severe reaction (oral pruritus and dyspnea) with a lower amount of protein (1.3 mg) compared to the analogous first-dose responder to fresh milk OFC of our previous study (urticarial rash after 0.1 ml administration equivalent to 3.43 mg milk protein).

	Model	ED01 mg protein (95% CI)	ED05 mg protein (95% CI)	ED10 mg protein (95% CI)	ED25 mg protein (95% CI)	ED50 mg protein (95% CI)
Milk	Log-normal	1.3 (0.4-4)	4.5 (1.8-11.2)	8.9 (4-19.6)	27.1 (14.3-51.5)	93.9 (53-166.1)
	Log-logistic	0.8 (0.2-3.5)	4.8 (1.6-13.9)	10.7 (4.3-26.4)	35.1 (17.4-70.7)	115 (63.5-208.2)
	Weibull	0.4 (0.1-2.7)	3.9 (1.1-14)	10.4 (3.7-29.1)	40.4 (19.8-82.4)	132.1 (80.6-216.6)
Egg	Log-normal	6 (2.8-12.6)	14.9 (8.3-26.9)	24.3 (14.5-40.7)	54.9 (36.1-83.5)	135.7 (93.5-197)
	Log-logistic	4.4 (1.7-11.4)	15.9 (8-31.4)	28.3 (15.9-50.2)	66.1 (42.4-102.9)	154.2 (105.8-224.9)
	Weibull	2.2 (0.6-7.3)	11.7 (5-27.2)	24.6 (12.4-48.9)	69.5 (43-112.4)	172.5 (122.9-242.1)

Table 3. ED1, ED5, ED10, ED25 and ED50 (mg protein) of baked milk and baked egg. CI, Confidence interval; ED, eliciting dose; ED01, ED05, ED10, ED25, ED50: cumulative amount of food protein predicted to cause an allergic reaction in 1%, 5%, 10%, 25% or 50% of the food allergic population, respectively.

The prevalence of patients who reacted to baked milk with systemic reaction (Grade 4 Sampson) was higher than after fresh milk OFC (34.2% vs 18.4%): this indicates that lower threshold could entail higher probability for severe reactions, running again the contrary common wisdom that there is no correlation between the eliciting dose and the severity of the subsequent reaction.⁵⁶

In our group, cutaneous reactions were the most frequent manifestations: 50 of 87 positive patients (57.4%) developed a skin symptom (mainly urticarial eruptions) during OFC, without appreciable differences between those allergic to milk and those allergic to egg. However, we discovered a food-related variation in the number of kids who had respiratory vs gastrointestinal symptoms at OFC. Gastrointestinal symptoms were seen more frequently in the baked egg group, with 46.9% experiencing vomiting, compared with 34.2% ($p < 0.05$) in the baked milk group. Children in the baked milk group experienced dyspnea and other respiratory symptoms at a rate of 31.5% and 36.8%, respectively, compared to only 7.9% ($p < 0.005$) and 13.1% ($p < 0.005$) for the baked egg group. This underlines the different behaviors between the 2 types of allergies, with milk-allergic children more prone to respiratory symptoms.

The rate of epinephrine-requiring anaphylaxis following OFC was similar in both groups; 4.9% (baked milk, 2 patients) versus 1.9% (baked egg, 1 patient); none required a second epinephrine dose. The use of bronchodilators differed significantly between the 2 groups, with 16 patients (39%) in the baked milk group compared to only 1 patient in the baked egg group ($p < 0.001$). Seven of the anaphylactic patients to baked milk, vs just 2 of those developing anaphylaxis to baked egg, had a history of asthma ($p = 0.13$). Again, this indicates that baked milk allergy is more likely to involve the respiratory tract. In the past, several suggestions linked cow's milk allergy to asthma and recurrent respiratory infections.⁵⁷⁻⁵⁹

These results are in line with earlier research, which found a greater prevalence of gastrointestinal symptoms in baked vs non-baked egg OFCs^{34,40,60,61} as well as a higher incidence of

respiratory symptoms in baked versus non-baked milk challenges.⁶¹ In our group, no patient experienced a Group 5 systemic reaction, most likely because of the skilled staff's quick response at the first appearance of objective symptoms.

Apart from the obvious limitation due to the single-center study design, our study presents methodological characteristics that could limit its clinical meaning. For feasibility reasons, OFCs performed with baked products contain a lower quantity of allergenic proteins than those possible with fresh products. In our 'baked' OFCs, every step-dose and total amount of milk or egg protein are lower in baked than in fresh OFC protocol: we administered a total amount of 0.8 g of milk protein compared with the 4.9 g used in our fresh milk OFC⁴⁵ and in similar studies.^{36,37,63} The total amount of egg protein we administered as egg biscuits was also lower (1.1 g) than for raw egg OFC (8.6 g). Other studies administered a total egg protein ranging from 1 g⁶⁴ to 2.2 g.^{34,35,63,64} If from a theoretical point of view this can be considered a limitation, from a practical point of view it reflects the impossibility of administering during OFCs quantities of baked products significantly higher than those possibly consumed during real life: our OFCs reflect reference doses.

This study suggests additional considerations regarding the clinical presentation of milk/egg allergy. First, compared with the OFC outcomes of children tolerant to baked, the number of positive results is lower: 17.9% and 26.4%, for baked egg and milk respectively, compared with 26.1% and 34.5% of OFC with fresh milk and egg. This indicates that when a child is allergic to milk or eggs, pediatricians and families tend to adopt prudent avoidance behaviors for baked foods, which does not correspond to reality. Therefore, carrying out tests with baked foods can help a good number of children free themselves from unnecessary dietary constraints.

Second, when a milk/egg allergic child reacts to baked forms, her clinical characteristics show more severity. Compared with children baked-tolerant recruited in the same setting and in the same timeframe,⁴⁵ they display a greater risk of severe reactions (19.5% vs. 12.1%), the need to resort to the emergency room (8.5% vs. 5.2%), and the use

of adrenaline (9.8% vs. 5.8%). This difference in severity of the allergy also explains the different performance of diagnostic tests in the populations of children who react to baked egg compared to those who do not react to it.⁶⁵ These individuals are likely to exhibit more psychosocial burden than their counterparts with CMA who are not allergic to baked forms.⁶⁶

Third, as in our caseload, the mean age was superior to the median, we confirm that baked food allergy is more frequent in younger ages and that milk and egg allergies fade over time.^{47,67}

Taken together, the data suggest that milk is a more dangerous food allergen than egg, in line with epidemiological studies assessing the severity of food reactions, where milk predominates over egg.⁶⁸

The significant correlation between milk sIgE level and individual threshold agrees with previous studies, which evaluated it as a positive predictive value for oral food challenge outcome⁶⁹⁻⁷¹ and specifically for individual threshold dose.⁷² We found no statistical correlation between patients' individual threshold and their age, gender and/or SPT levels in both our studies. However, we evaluated a sufficient sample size to allow for accurate estimations of population dose-threshold distributions, but this may not assess a predictive value for demographic and/or diagnostic variables as a predictor of individual threshold and/or positive outcome of challenge.

As we had previously reported, it will be ideal to validate the data within the subjects by comparison of the reproducible doses elicited at least among the patients who have undergone repeated OFCs and/or among those who have tolerated baked milk and had reacted to the OFC of fresh milk.⁷³

A limitation of our study is the insufficient number of patients with simultaneous allergies to both milk and egg who had positive OFCs for both allergens, which prevented us from analyzing the eliciting doses for these patients. Further studies with larger sample sizes are needed to adequately determine the eliciting doses for individuals with concurrent egg and milk allergies.

In conclusion, while fresh and baked milk EDs were equivalent in our evaluations, egg EDs were

greater than those previously reported (Fig. 2c and d). Establishing the ED01 for patients allergic to baked egg between 2.2 and 6 mg, our data document that this reactivity is significantly greater than that of patients tolerant to baked egg, whose ED01 is 14.4–29.7 mg. However, the more sensitive threshold of baked egg-allergic children remains higher than the thresholds used as the limit for PAL.^{4,6} Should these data be confirmed by direct comparison of reactivity to raw versus baked forms within the same patients, we hypothesize that egg-allergic children who tolerate baked egg, and possibly even some who react to it, may not need to avoid all foods that may contain egg. However, this recommendation should be made with caution, pending further studies to verify the safety and tolerance levels for these children. In addition, we open the possibility of adopting a less conservative threshold for egg PAL when the contamination happens in baked products. Should our results be confirmed, this change might exempt food producers from the need for precautionary labelling of egg traces in baked foods, aligning more closely with the actual tolerance possibilities. This could benefit both consumers with egg allergies and food producers.

Authors' consent for publication

All authors have read and consent to approval of the final manuscript.

Abbreviations

ED01, dose predicted to elicit allergic reactions in 1% of patients; ED05, dose predicted to elicit allergic reactions in 5% of patients; ICSA, Interval-Censoring Survival Analysis; LOAEL, Low Observed Adverse Effect Level; NOAEL, No Observed Adverse Effect Level; OFC, Oral Food Challenge; sIgE, specific IgE; SPT, Skin Prick Test.

Availability of data and materials

All data is available to the readers in the tables of the manuscript and references.

Author contributions

RLV developed the concept, prepared the infrastructure of the study, elaborated the data, performed the statistical analysis, and contributed made the draft. AF initiated the concept and contributed made the first draft. CR, SU, LD, VC, and VF administered the OFCs, evaluated the clinical data, included them in the database and contributed to the discussion. DU, DZ and FDG collaborated to the inclusion

of data in the database, collaborated to the statistical analysis, and contributed to the discussion.

Ethics approval

This study protocol was reviewed and approved by the Ethics Committee.

Submission declaration

This manuscript is original and has not been published, nor is it currently under consideration for publication elsewhere.

Funding

This work was supported by the Italian Ministry of Health of Italy with "Current Research funds".

Declaration of competing interest

The authors declare that they have no conflicts of interest.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.waojou.2024.101012>.

Author details

^aAllergy Unit, Piazza S. Onofrio Bambino Gesù Children's Hospital, IRCCS, 00165, Rome, Holy See, Italy. ^bAllergy Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. ^cDepartment of the Woman, the Child, of General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, Italy. ^dDepartment of Systems Medicine, The School of Pediatrics, University of Rome "Tor Vergata", Rome, Italy. ^eARPA Lazio, Regional Agency for Environmental Protection, Rome, Italy.

REFERENCES

1. Graham F, Fiocchi A. The importance of threshold dose-distribution data for priority allergens and the need for future studies. *Allergy*. 2022 Oct 28;77(10):2886–2887.
2. Muraro A, de Silva D, Halken S, et al. Managing food allergy: GA2LEN guideline 2022. *World Allergy Organization Journal*. 2022;15(9).
3. de Silva D, Rodríguez del Río P, de Jong NW, et al. Allergen immunotherapy and/or biologicals for IgE-mediated food allergy: a systematic review and meta-analysis. *Allergy*. 2022 Jun 19;77(6):1852–1862.
4. Report M. *Risk Assessment of Food Allergens. Part 2: Review and Establish Threshold Levels in Foods for the Priority Allergens*. *Risk Assessment of Food Allergens. Part 2: Review and Establish Threshold Levels in Foods for the Priority Allergens*. FAO; 2022.
5. Remington BC, Westerhout J, Meima MY, et al. Updated population minimal eliciting dose distributions for use in risk assessment of 14 priority food allergens. *Food Chem Toxicol*. 2020 May;139, 111259.

6. Houben GF, Baumert JL, Blom WM, et al. Full range of population Eliciting Dose values for 14 priority allergenic foods and recommendations for use in risk characterization. *Food Chem Toxicol.* 2020 Dec;146, 111831.
7. Wheeler MW, Westerhout J, Baumert JL, Remington BC. Bayesian stacked parametric survival with frailty components and interval-censored failure times: an application to food allergy risk. *Risk Anal.* 2021 Jan 16;41(1):56-66.
8. Turner PJ, d'Art YM, Duca B, et al. Single-dose oral challenges to validate eliciting doses in children with cow's milk allergy. *Pediatr Allergy Immunol.* 2021;32(5):1056-1065.
9. Baehler P, Chad Z, Gurbindo C, Bonin AP, Bouthillier L, Seidman EG. Distinct patterns of cow's milk allergy in infancy defined by prolonged, two-stage double-blind, placebo-controlled food challenges. *Clin Exp Allergy.* 1996 Mar;26(3):254-261.
10. Bellach J, Schwarz V, Ahrens B, et al. Randomized placebo-controlled trial of hen's egg consumption for primary prevention in infants. *J Allergy Clin Immunol.* 2017 May;139(5):1591-1599.e2.
11. Benhamou AH, Zamora SA, Eigenmann PA. Correlation between specific immunoglobulin E levels and the severity of reactions in egg allergic patients. *Pediatr Allergy Immunol.* 2008 Mar 13;19(2):173-179.
12. Caffarelli C, Cavagni G, Giordano S, Stapane I, Rossi C. Relationship between oral challenges with previously uningested egg and egg-specific IgE antibodies and skin prick tests in infants with food allergy. *J Allergy Clin Immunol.* 1995 Jun;95(6):1215-1220.
13. Dello Iacono I, Tripodi S, Calvani M, Panetta V, Verga MC, Miceli Sopo S. Specific oral tolerance induction with raw hen's egg in children with very severe egg allergy: a randomized controlled trial. *Pediatr Allergy Immunol.* 2013 Feb 9;24(1):66-74.
14. Escudero C, Sánchez-García S, Rodríguez del Río P, et al. Dehydrated egg white: an allergen source for improving efficacy and safety in the diagnosis and treatment for egg allergy. *Pediatr Allergy Immunol.* 2013 May 3;24(3):263-269.
15. Faraj Z, Kim HL. Skin prick testing with extensively heated milk or egg products helps predict the outcome of an oral food challenge: a retrospective analysis. *Allergy Asthma Clin Immunol.* 2012 Dec 16;8(1):5.
16. Knight A, Shreffler W, Sampson H, et al. Skin prick test to egg white provides additional diagnostic utility to serum egg white-specific IgE antibody concentration in children. *J Allergy Clin Immunol.* 2006 Apr;117(4):842-847.
17. Meglio P, Giampietro PG, Carello R, Gabriele I, Avitabile S, Galli E. Oral food desensitization in children with IgE-mediated hen's egg allergy: a new protocol with raw hen's egg. *Pediatr Allergy Immunol.* 2013 Feb 13;24(1):75-83.
18. Morisset M, Moneret-Vautrin DA, Guenard L, et al. Oral desensitization in children with milk and egg allergies obtains recovery in a significant proportion of cases. A randomized study in 60 children with cow's milk allergy and 90 children with egg allergy. *Eur Ann Allergy Clin Immunol.* 2007 Jan;39(1):12-19.
19. Morisset M, Moneret-Vautrin DA, Kanny G, et al. Thresholds of clinical reactivity to milk, egg, peanut and sesame in immunoglobulin E-dependent allergies: evaluation by double-blind or single-blind placebo-controlled oral challenges. *Clin Exp Allergy.* 2003 Aug 5;33(8):1046-1051.
20. Nørgaard A, Bindslev-Jensen C. Egg and milk allergy in adults. *Allergy.* 1992 Oct 28;47(5):503-509.
21. Pérez-Rangel I, Rodríguez del Río P, Escudero C, Sánchez-García S, Sánchez-Hernández JJ, Ibáñez MD. Efficacy and safety of high-dose rush oral immunotherapy in persistent egg allergic children. *Ann Allergy Asthma Immunol.* 2017 Mar;118(3):356-364.e3.
22. Vazquez-Ortiz M, Alvaro M, Piquer M, et al. Baseline specific <scp>I</scp> g <scp>E</scp> levels are useful to predict safety of oral immunotherapy in egg-allergic children. *Clin Exp Allergy.* 2014 Jan 20;44(1):130-141.
23. Winberg A, West CE, Strinnholm Å, Nordström L, Hedman L, Rönmark E. Assessment of allergy to milk, egg, cod, and wheat in Swedish schoolchildren: a population based cohort study. *Wiley as. PLoS One.* 2015 Jul 2;10(7), e0131804.
24. Caminiti L, Passalacqua G, Barberi S, et al. A new protocol for specific oral tolerance induction in children with IgE-mediated cow's milk allergy. *Allergy Asthma Proc.* 2009 Jul 1;30(4):443-448.
25. Dambacher WM, de Kort EH, Blom WM, Houben GF, de Vries E. Double-blind placebo-controlled food challenges in children with alleged cow's milk allergy: prevention of unnecessary elimination diets and determination of eliciting doses. *Nutr J.* 2013 Dec 8;12(1):22.
26. Devenney I, Norrman G, Oldaeus G, Strömberg L, Fälth-Magnusson K. A new model for low-dose food challenge in children with allergy to milk or egg. *Acta Paediatr.* 2006 Sep 29;95(9):1133-1139.
27. Fiocchi A, Travaini M, D'Auria E, Banderali G, Bernardo L, Riva E. Tolerance to a rice hydrolysate formula in children allergic to cow's milk and soy. *Clin Exp Allergy.* 2003 Nov 7;33(11):1576-1580.
28. Flinterman AE, Knulst AC, Meijer Y, Bruijnzeel-Koomen CAFM, Pasmans SGMA. Acute allergic reactions in children with AEDS after prolonged cow's milk elimination diets. *Allergy.* 2006 Mar 23;61(3):370-374.
29. Hill DJ, Ford RPK, Shelton MJ, Hosking CS. A study of 100 infants and young children with cow's milk allergy. *Clin Rev Allergy.* 1984 May;2(2):125-142.
30. Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. *J Allergy Clin Immunol.* 2012 Feb;129(2):448-455.e5.
31. Longo G, Barbi E, Berti I, et al. Specific oral tolerance induction in children with very severe cow's milk-induced reactions. *J Allergy Clin Immunol.* 2008 Feb;121(2):343-347.
32. Skripak JM, Nash SD, Rowley H, et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. *J Allergy Clin Immunol.* 2008 Dec;122(6):1154-1160.
33. Leau A, Denery-Papini S, Bodinier M, Dijk W. Tolerance to heated egg in egg allergy: explanations and implications for prevention and treatment. *Clin Transl Allergy.* 2023 Dec 21;13(12).
34. Lieberman JA, Huang FR, Sampson HA, Nowak-Węgrzyn A. Outcomes of 100 consecutive open, baked-egg oral food challenges in the allergy office. *J Allergy Clin Immunol.* 2012 Jun;129(6):1682-1684.e2.

35. Lemon-Mulé H, Sampson HA, Sicherer SH, Shreffler WG, Noone S, Nowak-Węgrzyn A. Immunologic changes in children with egg allergy ingesting extensively heated egg. *J Allergy Clin Immunol*. 2008 Nov;122(5):977-983.e1.
36. Nowak-Węgrzyn A, Bloom KA, Sicherer SH, et al. Tolerance to extensively heated milk in children with cow's milk allergy. *J Allergy Clin Immunol*. 2008 Aug;122(2):342-347.e2.
37. Agyemang A, Feuille E, Tang J, Steinwandtner I, Sampson H, Nowak-Węgrzyn A. Outcomes of 84 consecutive open food challenges to extensively heated (baked) milk in the allergy office. *J Allergy Clin Immunol Pract*. 2018 Mar;6(2):653-655.e2.
38. Mehr S, Turner PJ, Joshi P, Wong M, Campbell DE. Safety and clinical predictors of reacting to extensively heated cow's milk challenge in cow's milk-allergic children. *Ann Allergy Asthma Immunol*. 2014 Oct;113(4):425-429.
39. Vilar LK, Araújo FA, Santos TP, Menezes TT, Cheik MF, Segundo GRS. Baked tolerance in cow's milk allergy: quite frequent, hard to predict. *Int Arch Allergy Immunol*. 2021;182(4):319-323.
40. Aquilante BP, Castro APBM, Yonamine GH, et al. IgE-mediated cow's milk allergy in Brazilian children: outcomes of oral food challenge. *World Allergy Organization Journal*. 2023 May;16(5), 100781.
41. Konstantinou GN, Giavi S, Kalobatsou A, et al. Consumption of heat-treated egg by children allergic or sensitized to egg can affect the natural course of egg allergy: hypothesis-generating observations. *J Allergy Clin Immunol*. 2008 Aug;122(2):414-415.
42. Osborne NJ, Koplin JJ, Martin PE, et al. Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. *J Allergy Clin Immunol*. 2011 Mar;127(3):668-676.e2.
43. Capucilli P, Cianferoni A, Fiedler J, et al. Differences in egg and milk food challenge outcomes based on tolerance to the baked form. *Ann Allergy Asthma Immunol*. 2018 Nov;121(5):580-587.
44. Remington BC, Westerhout J, Campbell DE, Turner PJ. Minimal impact of extensive heating of hen's egg and cow's milk in a food matrix on threshold dose-distribution curves. *Allergy*. 2017 Nov 26;72(11):1816-1819.
45. Valluzzi RL, Riccardi C, Arasi S, et al. Cow's milk and egg protein threshold dose distributions in children tolerant to beef, baked milk, and baked egg. *Allergy*. 2022 Oct 13;77(10):3052-3060.
46. Terracciano L, Bouygue GR, Sarratud T, Veglia F, Martelli A, Fiocchi A. Impact of dietary regimen on the duration of cow's milk allergy: a random allocation study. *Clin Exp Allergy*. 2010 Apr 11;40(4):637-642.
47. Bartnikas LM, Sheehan WJ, Hoffman EB, et al. Predicting food challenge outcomes for baked milk: role of specific IgE and skin prick testing. *Ann Allergy Asthma Immunol*. 2012 Nov;109(5):309-313.e1.
48. Fierro V, Marzano V, Monaci L, et al. Threshold of reactivity and tolerance to precautionary allergen-labelled biscuits of baked milk- and egg-allergic children. *Nutrients*. 2021 Dec 18;13(12):4540.
49. Nowak-Węgrzyn A, Assa'ad AH, Bahna SL, Bock SA, Sicherer SH, Teuber SS. Work Group report: oral food challenge testing. *J Allergy Clin Immunol*. 2009 Jun;123(6):S365-S383.
50. Keil T, McBride D, Grimshaw K, et al. The multinational birth cohort of EuroPrevall: background, aims and methods. *Allergy*. 2010 Apr;65(4):482-490.
51. Sampson HA. Anaphylaxis and emergency treatment. *Pediatrics*. 2003 Jun;111(6 Pt 3):1601-1608.
52. Taylor SL, Moneret-Vautrin DA, Crevel RWR, et al. Threshold dose for peanut: risk characterization based upon diagnostic oral challenge of a series of 286 peanut-allergic individuals. *Food Chem Toxicol*. 2010 Mar;48(3):814-819.
53. Spanjersberg MQI, Kruizinga AG, Rennen MAJ, Houben GF. Risk assessment and food allergy: the probabilistic model applied to allergens. *Food Chem Toxicol*. 2007 Jan;45(1):49-54.
54. Upton JEM, Lanser BJ, Bird JA, Nowak-Węgrzyn A. Baked milk and baked egg survey: a work group report of the AAAAI adverse reactions to foods committee. *J Allergy Clin Immunol Pract*. 2023 Aug;11(8):2335-2344.e4.
55. Allen KJ, Remington BC, Baumert JL, et al. Allergen reference doses for precautionary labeling (VITAL 2.0): clinical implications. *J Allergy Clin Immunol*. 2014;133(1):156-164.
56. Arasi S, Nurmatov U, Dunn-Galvin A, et al. Consensus on DEfinition of Food Allergy SEverity (DEFASE) an integrated mixed methods systematic review. *World Allergy Organization Journal*. 2021 Mar;14(3), 100503.
57. Ngamphaiboon J, Chatchatee P, Thongkaew T. Cow's milk allergy in Thai children. *Asian Pac J Allergy Immunol*. 2008 Dec;26(4):199-204.
58. Fiocchi A, Knol J, Koletzko S, et al. Early-life respiratory infections in infants with cow's milk allergy: an expert opinion on the available evidence and recommendations for future research. *Nutrients*. 2021 Oct 26;13(11):3795.
59. Darougat S, Mansouri M, Hassani S, Sohrabi MR, Hashemitari P. The effect of a cow's milk-free diet on asthma control in children: a quasi-experimental study. *Afr J Clin Exp Immunol*. 2021;10(1):8-16.
60. Gupta M, Grossmann L, Spergel J, Cianferoni A. Egg food challenges are associated with more gastrointestinal reactions. *Children*. 2015 Aug 17;2(3):371-381.
61. Al Enezi M, Lack G, Fox AT, Anagnostou K. Safety and allergic reaction profiles of children undergoing baked milk and egg challenges: a 6-year experience from a pediatric tertiary referral center. *J Allergy Clin Immunol Pract*. 2018 Mar;6(2):674-676.
62. Mortz CG, Parke L, Rasmussen HM, Kjaer HF, Bindslev-Jensen C. A randomized, double-blind placebo-controlled study on the efficacy of Omalizumab on food allergy threshold in children with severe food allergy. *Allergy*. 2024 Apr 17;79(4):964-976.
63. Sirin Kose S, Asilsoy S, Uzuner N, Karaman O, Anal O. Outcomes of baked milk and egg challenge in cow's milk and hen's egg allergy: can tolerance be predicted with allergen-specific IgE and prick-to-prick test? *Int Arch Allergy Immunol*. 2019;180(4):264-273.
64. Turner PJ, Mehr S, Joshi P, et al. Safety of food challenges to extensively heated egg in egg-allergic children: a prospective cohort study. *Pediatr Allergy Immunol*. 2013 Aug 16;24(5):450-455.

65. Marques-Mejias A, Radulovic S, Foong RX, et al. Partial egg consumption modifies the diagnostic performance of allergy tests to predict outcome of double-blind placebo-controlled food challenges to egg. *J Allergy Clin Immunol Pract*. 2024 Mar;12(3):660-669.e5.
66. Warren CM, Agrawal A, Gandhi D, Gupta RS. The US population-level burden of cow's milk allergy. *World Allergy Organization Journal*. 2022 Apr;15(4), 100644.
67. Koutlas N, Stallings A, Hall G, Zhou C, Kim-Chang J, Mousallem T. Pediatric oral food challenges in the outpatient setting: a single-center experience. *J Allergy Clin Immunol: Global*. 2024 Feb;3(1), 100187.
68. Baseggio Conrado A, Ierodiakonou D, Gowland MH, Boyle RJ, Turner PJ. Food anaphylaxis in the United Kingdom: analysis of national data, 1998-2018. *BMJ*. 2021 Feb 17;372, n251.
69. Boyano-Martínez T, García-Ara C, Pedrosa M, Díaz-Pena JM, Quirce S. Accidental allergic reactions in children allergic to cow's milk proteins. *J Allergy Clin Immunol*. 2009 Apr;123(4): 883-888.
70. Boyano-Martínez T, Pedrosa M, Quirce S, García-Ara C. Accidental allergic reactions in children allergic to hen's egg. *J Investig Allergol Clin Immunol*. 2012;22(2):109-115.
71. Rodríguez-Catalán J, González-Arias AM, Vallespin Casas A, Del Río Camacho G. Specific IgE levels as an outcome predictor in egg-allergic children. *Allergol Immunopathol*. 2021 Jan 8;49(1):79-86.
72. García-Ara MC, Boyano MT, Díaz-Pena JM, Quirce S. Eliciting doses of positive challenge test in cow's milk allergy are related to cow's milk specific IgE levels. *Allergol Immunopathol*. 2008 Dec;36(6):315-319.
73. Blom WM, Michelsen-Huisman AD, van Os-Medendorp H, et al. Accidental food allergy reactions: products and undeclared ingredients. *J Allergy Clin Immunol*. 2018 Sep;142(3):865-875.